BioCatalyst

Pembrolizumab, MK-4830, Belzutifan, Lenvatinib — catalyst calendar

1 verified catalyst event(s) referencing Pembrolizumab, MK-4830, Belzutifan, Lenvatinib, each linked to its official source. Verified as of 2026-08-06.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-08-21
in 15d
ESTIMATED
 READOUT
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participan
Phase 1/2 · Carcinoma, Renal Cell
 Merck Sharp & Dohme LLC Pembrolizumab, MK-4830, Belzutifan, Lenv ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.